# A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease

> **NCT06226545** · PHASE2 · COMPLETED · sponsor: **Lassen Therapeutics Inc.** · enrollment: 41 (actual)

## Conditions studied

- Thyroid Eye Disease
- Graves Ophthalmopathy
- Graves Orbitopathy
- Thyroid Associated Ophthalmopathy
- Endocrine System Diseases
- Orbital Diseases
- Proptosis
- Eye Diseases

## Interventions

- **DRUG:** LASN01
- **DRUG:** LASN01
- **DRUG:** Placebo
- **DRUG:** LASN01

## Key facts

- **NCT ID:** NCT06226545
- **Lead sponsor:** Lassen Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-03-05
- **Primary completion:** 2025-04-22
- **Final completion:** 2025-04-22
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-03-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226545, "A Study to Evaluate the Efficacy and Safety of LASN01 in Patients With Thyroid Eye Disease". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06226545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*